Autoimmune Myelopathy Testing - Mayo Clinic Laboratories
Mayo Clinic Laboratories is the only laboratory in the world to offer testing for a novel form of autoimmune meningoencephalomyelitis.
Thrombotic microangiopathy (TMA) - Insights
View our comprehensive testing suite designed to confirm diagnosis and facilitate treatment of thrombotic microangiopathy.
Learn more about Mayo Clinic Laboratories testing for pregnancy loss, which can help determine causes and risk of recurrence for future pregnancies.
CPT codes and LOINC update: January 2024 - Insights
This page includes updates posted to Mayo Clinic Labs during the month of January.
August 2021 - Clinical Microbiology and Infectious Disease Pathology - Insights
This "Pathways" program provides a Clinical Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Clinical Microbiology.
September 2023 - Cardiovascular Pathology - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Cardiovascular Pathology.
Staffing to Workload in Phlebotomy Areas: Off-Site Operational Needs - Insights
Mike Baisch, Principal Systems Engineer at Mayo Clinic, discusses staffing to workload in phlebotomy areas with a focus on off-site operational needs, including paid time off and unpaid time off.
The National Kidney Foundation, the American Society for Clinical Pathology, and the nation’s leading laboratories and clinical laboratory societies have announced a new collaboration to remove barriers to testing for chronic kidney...
Mayo Clinic Research Advances Diagnostics to Lead COVID-19 Pandemic Response - Insights
When COVID-19 spread across the U.S. in early March, Mayo Clinic’s Advanced Diagnostic Laboratory urgently responded.
Mayo Clinic Researchers Find New Way to Improve Newborn Screening of Pompe Disease - Insights
Researchers at Mayo Clinic have discovered a second-tier test for Pompe disease that has been shown to improve the specificity of newborn screening for the disorder, which would lower the rate of false-positive results.